Group 1 - The core viewpoint of the article highlights the performance and market position of New Mile Health Technology Group Co., Ltd, which operates in the medical services and pharmaceutical industry [1] - As of July 8, the closing price of New Mile was 2.14 yuan, reflecting a 2.39% increase, with a rolling PE ratio of 64.65 times and a total market capitalization of 7.249 billion yuan [1] - The average PE ratio for the medical services industry is 42.77 times, with a median of 47.19 times, positioning New Mile at the 34th rank within the industry [1][2] Group 2 - In terms of capital flow, on July 8, New Mile experienced a net outflow of 5.392 million yuan, continuing a trend of outflows over the past five days, totaling 127.0872 million yuan [1] - The company has been focused on pharmaceutical production for over 20 years, with its main products including traditional Chinese medicine, particularly the "Duyiwei" brand, which is recognized in the 2020 edition of the Chinese Pharmacopoeia [1] - The latest financial results for Q1 2025 show that New Mile achieved a revenue of 796 million yuan, a year-on-year decrease of 16.49%, and a net profit of 25.652 million yuan, down 9.35%, with a gross profit margin of 27.96% [1]

Group 1 - The core viewpoint is that the innovative pharmaceutical sector is experiencing significant growth, driven by policy changes and market dynamics, with a notable increase in ETF performance and trading volume [1][2] - As of July 7, the innovative pharmaceutical ETF (560900) reached a new high in scale at 414.453 million yuan, with the latest share count at 47.9691 million, marking a one-month peak [1] - The National Healthcare Security Administration reported that since its establishment in 2018, 149 innovative drugs have been included in the medical insurance catalog, leading to a cumulative payment of 410 billion yuan for negotiated drugs, significantly boosting sales and improving drug accessibility [1] Group 2 - Donghai Securities views innovative drugs as the core investment theme in the biopharmaceutical sector, anticipating a period of rapid development due to the introduction of commercial insurance catalogs and the opening of payment spaces [2] - The overseas market for innovative drugs is expected to expand continuously, supported by large-scale business development transactions and increasing international competitiveness [2] - Morgan Asset Management is integrating its "Global Vision Investment Technology" product line to help investors capitalize on opportunities in quality technology companies amid a new wave of technological advancements driven by AI [2] Group 3 - Morgan's passive investment options include the Morgan Hang Seng Technology ETF and the Morgan China Innovative Pharmaceutical Industry ETF, providing investors with easy access to technology and pharmaceutical assets [3] - The Morgan Nasdaq 100 Index Fund offers a straightforward way to invest in global technology leaders [3]

Group 1 - The Hong Kong stock market's innovative drug sector continues to strengthen, with Rongchang Biologics rising over 7% [1] - Junshi Biosciences increased by more than 4% [1] - Tigermed (300347) and Zhaoyan New Drug (603127) both saw gains of over 3% [1] Group 2 - Innovent Biologics and Kanglong Chemical (300759) experienced increases of over 2% [1]

致：香港交易及結算所有限公司 公司名稱: 康龍化成（北京）新藥技術股份有限公司 (於中華人民共和國註冊成立的股份有限公司） 呈交日期: 2025年7月7日 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年6月30日 狀態: 新提交 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 03759 | 說明 | H股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 301,537,125 | RMB | | 1 RMB | | 301,537,125 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 301,537,125 | RMB | | 1 RMB | | 301,537,125 | | ...

截至7月7日收盘，CRO概念下跌1.07%，位居概念板块跌幅榜前列，板块内，汇宇制药、*ST双成、睿 智医药等跌幅居前，股价上涨的有15只，涨幅居前的有诺思格、昭衍新药、翰宇药业等，分别上涨 3.03%、2.24%、2.11%。 | 002675 | 东诚药业 | -3.15 | 2.11 | -1460.10 | | --- | --- | --- | --- | --- | | 002821 | 凯莱英 | -2.94 | 1.10 | -1440.10 | | 688117 | 圣诺生物 | -0.77 | 7.83 | -1379.21 | | 603229 | 奥翔药业 | -2.05 | 1.37 | -1331.54 | | 300261 | 雅本化学 | -0.14 | 1.47 | -1240.44 | | 300363 | 博腾股份 | -1.98 | 1.86 | -1086.79 | | 301277 | 新天地 | -0.62 | 7.98 | -1072.75 | | 301509 | 金凯生科 | -0.61 | 7.64 | -985.87 | | 603538 | 美诺华 | ...

Group 1 - The core viewpoint indicates that the Chinese pharmaceutical sector, particularly the innovative drug segment, is poised for a rebound in the second half of the year, with significant growth in the approval of innovative drugs and medical devices [1][2] - As of July 4, the Hong Kong pharmaceutical ETF has seen a net value increase of 71.46% over the past year, reflecting strong market performance [1] - In the first half of the year, China approved 43 innovative drugs and 45 innovative medical devices, marking year-on-year growth of 59% and 87% respectively, showcasing the positive impact of reform policies on industry development [1] Group 2 - The CSI Hong Kong Stock Connect Healthcare Index consists of 50 liquid and large-cap healthcare companies, with the top ten stocks accounting for 59.44% of the index [4] - The top ten weighted stocks in the CSI Hong Kong Stock Connect Healthcare Index include companies like Innovent Biologics and WuXi Biologics, with varying performance in terms of stock price changes [6] - The CSI Medical and Medical Device Innovation Index includes 30 companies with strong profitability and growth potential, with the top ten stocks representing 63.62% of the index [7] Group 3 - The latest scale of the Medical Innovation ETF has reached 1.478 billion yuan, indicating a growing interest in the sector [2] - The performance of individual stocks within the Medical Innovation ETF shows mixed results, with some stocks like TianTan Bio leading gains while others like Sangfor Technologies are experiencing declines [9] - The index aims to reflect the overall performance of profitable and growth-oriented pharmaceutical and medical device companies [7]

创新药行情持续火热，建议关注 PD-1/L1 双抗及多抗 [Table_Industry] 医药生物行业周报 [Table_ReportTime] 2025 年 7 月 6 日 证券研究报告 行业研究 [Table_ReportType] 行业周报 医药生物 医药生物 投资评级 看好 上次评级 看好 [Table_A 唐爱金 uthor 医药首席分析师 ] 执业编号：S1500523080002 邮 箱：tangaijin@cindasc.com 贺鑫 医药行业分析师 执业编号：S1500524120003 邮 箱：hexin1@cindasc.com 曹佳琳 医药行业分析师 执业编号：S1500523080011 邮 箱：caojialin@cindasc.com 章钟涛 医药行业分析师 执业编号：S1500524030003 邮 箱：zhangzhongtao@cindasc.com 赵丹 医药行业分析师 执业编号：S1500524120002 邮 箱：zhaodan@cindasc.com 信达证券股份有限公司 CINDA SECURITIES CO.,LTD 北京市西城区宣武门西大街甲127号金隅大厦 ...

Company Overview - New Mile Health Technology Group Co., Ltd. focuses on medical services and pharmaceutical industry, with a primary product line that includes medicines and medical products [1] - The company has over 20 years of experience in drug production, establishing a series of traditional Chinese medicine centered around the "Duyiwei" brand, which is recognized in the 2020 edition of the "Chinese Pharmacopoeia" [1] Financial Performance - For Q1 2025, the company reported a revenue of 796 million yuan, a year-on-year decrease of 16.49%, and a net profit of 25.65 million yuan, down 9.35% year-on-year, with a gross margin of 27.96% [1] - The current stock price is 2.17 yuan, reflecting a decline of 1.36%, with a rolling price-to-earnings (PE) ratio of 65.56 times [1] Market Position - The average PE ratio for the medical services industry is 41.66 times, with a median of 43.26 times, positioning New Mile at 34th place within the industry [2] - The company's total market capitalization is 7.351 billion yuan [2] Shareholder Information - As of June 10, 2025, New Mile has 64,494 shareholders, an increase of 419 since the last report, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1]

Group 1 - The core viewpoint of the news is the performance and holdings of the China Europe Medical Health Mixed Fund C, which has shown positive growth in recent months and has a significant concentration in its top ten stock holdings [1][3] - As of July 3, 2025, the latest net value of the fund is 1.6642 yuan, reflecting a growth of 1.50%. The fund's one-month return is 1.53%, six-month return is 14.38%, and year-to-date return is 10.32% [1] - The fund's top ten stock holdings account for a total of 55.30%, with significant positions in companies such as Heng Rui Pharmaceutical (10.60%), WuXi AppTec (9.95%), and Mindray Medical (5.21%) [1] Group 2 - The China Europe Medical Health Mixed Fund C was established on September 29, 2016, and as of March 31, 2025, it has a total scale of 15.566 billion yuan [1] - The fund manager, Ge Lan, has a background in biomedical engineering and has held various positions in research and fund management since joining China Europe Fund Management in October 2014 [2]

Company Overview - Wanbang Medical's closing price on July 3 was 43.46 yuan, with an increase of 1.31%, resulting in a rolling PE ratio of 42.80 times and a total market capitalization of 2.897 billion yuan [1] - The company ranks 30th in the medical services industry, which has an average PE ratio of 41.84 times and a median of 42.80 times [1] Institutional Holdings - As of the first quarter of 2025, three institutions held shares in Wanbang Medical, including two other entities and one fund, with a total holding of 1.5205 million shares valued at 6.2 million yuan [1] Business Operations - Wanbang Medical specializes in providing professional pharmaceutical research outsourcing services to pharmaceutical companies and other research institutions [1] - The main products include clinical trial site management (SMO), biological sample analysis (BA), data management and statistical analysis (DM/ST), prescription process research, quality research, and stability research [1] Financial Performance - In the first quarter of 2025, the company reported operating revenue of 71.0522 million yuan, a year-on-year decrease of 21.20%, and a net profit of 11.8493 million yuan, down 60.09% year-on-year, with a sales gross margin of 31.62% [1] Industry Comparison - The PE ratios for Wanbang Medical are compared to the industry averages, with the industry average PE at 41.84 times and the median at 42.80 times [2] - Other companies in the industry include WuXi AppTec with a PE of 18.17 times and a market cap of 203.123 billion yuan, and Kanglong Chemical with a PE of 23.40 times and a market cap of 43.726 billion yuan [2]